ArticleAmerican journal of translational research2025

Combination therapy with otilonium bromide and trimebutine maleate demonstrates significant clinical advantages in irritable bowel syndrome patients.

Dingfeng Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.